Bondarenko, I. and Sezer, A. and Kilickap, S. and Gümüs, M. and Özgüroğlu, M. and Gogishvili, M. and He, X. and Gullo, G. and Rietschel, P. and Quek, R.G. (2022) Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. Annals of Oncology, Vol.33 (Supp.2). S84-S85. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
![[img]](http://repo.dma.dp.ua/style/images/fileicons/text.png) |
Text
1-s2.0-S0923753422002551-main.pdf Download (130kB) |
Abstract
In this post hoc analysis of patients with laNSCLC and PD-L1 ≥50%, cemiplimab resulted in significant favourable overall change from BL in GHS/QoL and important cancer-related and lung cancerespecific symptoms versus chemo. PRO results further support the favourable benefit-risk profile of 1L cemiplimab versus chemo in laNSCLC with PD-L1 ≥50%. Clinical trial identification: NCT03088540.
| Item Type: | Article |
|---|---|
| Additional Information: | European Lung Cancer Congress (ELCC) 2022, 30 March-2 April 2022 |
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 31 May 2022 09:28 |
| Last Modified: | 31 May 2022 09:30 |
| URI: | http://repo.dma.dp.ua/id/eprint/7576 |
Actions (login required)
 |
View Item |
